Skip to main content
Explore URMC

menu

Amyloidosis: A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

Research Question:
Is daratumumab when given with three other drugs [cyclophosphamide, bortezomib (VELCADE®) and dexamethasone] useful for treating patients with Amyloid light chain Amyloidosis (also known as AL Amyloidosis)?

Basic Study Information

Purpose:
There are two treatment groups in this study. The study medication will be given in treatment cycles, and each cycle is 28 days long. Group A: Cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD). Group B: Daratumumab plus cyclophosphamide, bortezomib (VELCADE®) and dexamethasone (CyBorD)

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT03201965?term=AMY3001&rank=1
Study Reference #: IMMY17131

Lead Researcher (Principal Investigator)

Lead Researcher: Frank Passero

Study Contact Information

Study Coordinator: Andrew Bui
Phone: (585) 276-4405
Email: Andrew_Bui@URMC.Rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Amyloidosis

Return to Search